oral glp 1 drugs in development Emerging Trends the of GLP-1 Receptor Agonists GLP-1 Receptor Agonists | New

Description

26 The majority (67%) of the patients reviewed had a mean baseline HbA1c of 9.5% when therapy was initiated, which supports the theory of lack of action in response to abnormal findings

They arent without side effects

GLP-1R activity also promotes the transactivation of epidermal growth factor receptor (EGFR), which then signals through phosphoinositide 3-kinase (PI3K) and insulin receptor substrate-2 (IRS-2), and subsequently activates extracellular-signal-regulated kinase 1 and 2 (ERK1/2) and nuclear translocation of PKC to mediate -cell proliferation and differentiation (110, 114)

These challenges drive people to seek alternatives that provide the same medication at lower costs or with better availability

To understand whether the residual glucagon activity is a therapeutic target, fibroblast growth factor 21 (FGF21) and ketone bodies were measured as plasma markers indicative of chronic glucagon agonism